Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This study reviewed the use of microinfusion of microparticles (MMP®) with methotrexate for treating alopecia frontal fibrosante and found it reduced symptoms associated with the condition and improved specific scalp measurements, showing that the technique is safe and well-tolerated.

In this study, a combination treatment of microinfusion (MMP®) and topical minoxidil showed a modest increase in hair density in a 28-year-old woman with chronic telogen effluvium, particularly in the parieto-vertex region, suggesting potential benefits but underscoring the need for larger trials to confirm efficacy.

This article notes that low-dose systemic minoxidil combined with antiandrogen therapy is effective for treating female pattern hair loss, though hypertrichosis can occur in a significant percentage of patients.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

This study found that the MIRA technique, which customizes needle length and injection angle guided by ultrasound, improved structural and esthetic outcomes for cellulite treatment compared to standard methods.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

In this small study, topical minoxidil 2% was associated with an increase in normal hair shaft production in patients with Monilethrix without any reported side effects.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.